<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;ff=20230912060825&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;v=2.17.9.post6+86293ac&amp;ff=20230912060825&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 12 Sep 2023 10:08:26 +0000</lastbuilddate>
<pubDate>Mon, 11 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Catheter ablation improves outcomes in patients with AF and end-stage HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37697073/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 11. doi: 10.1038/s41569-023-00932-9. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37697073/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37697073</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00932-9>10.1038/s41569-023-00932-9</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37697073</guid>
<pubDate>Mon, 11 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-09-11</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Catheter ablation improves outcomes in patients with AF and end-stage HF</dc:title>
<dc:identifier>pmid:37697073</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00932-9</dc:identifier>
</item>
<item>
<title>Cardiac Pericyte Diversity in Infarct Remodeling: Not Just Vascular Support Cells?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37695834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 12;148(11):899-902. doi: 10.1161/CIRCULATIONAHA.123.065676. Epub 2023 Sep 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37695834/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37695834</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065676>10.1161/CIRCULATIONAHA.123.065676</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37695834</guid>
<pubDate>Mon, 11 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Thomas Moore-Morris</dc:creator>
<dc:creator>Sylvia M Evans</dc:creator>
<dc:date>2023-09-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiac Pericyte Diversity in Infarct Remodeling: Not Just Vascular Support Cells?</dc:title>
<dc:identifier>pmid:37695834</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065676</dc:identifier>
</item>
<item>
<title>Letter by Cosentino and Marino Regarding Article, "Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37695833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 12;148(11):906-907. doi: 10.1161/CIRCULATIONAHA.123.064000. Epub 2023 Sep 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37695833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37695833</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064000>10.1161/CIRCULATIONAHA.123.064000</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37695833</guid>
<pubDate>Mon, 11 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Marco Cosentino</dc:creator>
<dc:creator>Franca Marino</dc:creator>
<dc:date>2023-09-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Cosentino and Marino Regarding Article, "Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis"</dc:title>
<dc:identifier>pmid:37695833</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064000</dc:identifier>
</item>
<item>
<title>Prognostic Impact of Intravascular Imaging-Guided Percutaneous Coronary Intervention in Chronic Total Occlusion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37695832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 12;148(11):903-905. doi: 10.1161/CIRCULATIONAHA.123.065876. Epub 2023 Sep 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37695832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37695832</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065876>10.1161/CIRCULATIONAHA.123.065876</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37695832</guid>
<pubDate>Mon, 11 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>David Hong</dc:creator>
<dc:creator>Sang Min Kim</dc:creator>
<dc:creator>Sang Yeub Lee</dc:creator>
<dc:creator>Ki Hong Choi</dc:creator>
<dc:creator>Young Bin Song</dc:creator>
<dc:creator>Jong-Young Lee</dc:creator>
<dc:creator>Seung-Jae Lee</dc:creator>
<dc:creator>Kyeong Ho Yun</dc:creator>
<dc:creator>Jae Young Cho</dc:creator>
<dc:creator>Chan Joon Kim</dc:creator>
<dc:creator>Hyo-Suk Ahn</dc:creator>
<dc:creator>Chang-Wook Nam</dc:creator>
<dc:creator>Hyuck-Jun Yoon</dc:creator>
<dc:creator>Yong Hwan Park</dc:creator>
<dc:creator>Wang Soo Lee</dc:creator>
<dc:creator>Jin-Ok Jeong</dc:creator>
<dc:creator>Pil Sang Song</dc:creator>
<dc:creator>Joon-Hyung Doh</dc:creator>
<dc:creator>Sang-Ho Jo</dc:creator>
<dc:creator>Chang-Hwan Yoon</dc:creator>
<dc:creator>Min Gyu Kang</dc:creator>
<dc:creator>Jin-Sin Koh</dc:creator>
<dc:creator>Kwan Yong Lee</dc:creator>
<dc:creator>Young-Hyo Lim</dc:creator>
<dc:creator>Yun-Hyeong Cho</dc:creator>
<dc:creator>Jin-Man Cho</dc:creator>
<dc:creator>Woo Jin Jang</dc:creator>
<dc:creator>Kook-Jin Chun</dc:creator>
<dc:creator>Taek Kyu Park</dc:creator>
<dc:creator>Jeong Hoon Yang</dc:creator>
<dc:creator>Seung-Hyuk Choi</dc:creator>
<dc:creator>Hyeon-Cheol Gwon</dc:creator>
<dc:creator>Joo-Yong Hahn</dc:creator>
<dc:creator>Joo Myung Lee</dc:creator>
<dc:creator>RENOVATE-COMPLEX-PCI Investigators</dc:creator>
<dc:date>2023-09-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Prognostic Impact of Intravascular Imaging-Guided Percutaneous Coronary Intervention in Chronic Total Occlusion</dc:title>
<dc:identifier>pmid:37695832</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065876</dc:identifier>
</item>
<item>
<title>Why Novel Therapies in Preventive Cardiology May Face a Marathon, Not a Sprint</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37695831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 12;148(11):859-861. doi: 10.1161/CIRCULATIONAHA.122.063099. Epub 2023 Sep 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37695831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37695831</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063099>10.1161/CIRCULATIONAHA.122.063099</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37695831</guid>
<pubDate>Mon, 11 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Joanna S Cavalier</dc:creator>
<dc:creator>Nishant P Shah</dc:creator>
<dc:creator>Michael A Blazing</dc:creator>
<dc:date>2023-09-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Why Novel Therapies in Preventive Cardiology May Face a Marathon, Not a Sprint</dc:title>
<dc:identifier>pmid:37695831</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063099</dc:identifier>
</item>
<item>
<title>Letter by Schwartz and Prasad Regarding Article, "Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37695830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 12;148(11):908-909. doi: 10.1161/CIRCULATIONAHA.123.064414. Epub 2023 Sep 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37695830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37695830</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064414>10.1161/CIRCULATIONAHA.123.064414</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37695830</guid>
<pubDate>Mon, 11 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael David Schwartz</dc:creator>
<dc:creator>Kamla K Prasad</dc:creator>
<dc:date>2023-09-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Schwartz and Prasad Regarding Article, "Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis"</dc:title>
<dc:identifier>pmid:37695830</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064414</dc:identifier>
</item>
<item>
<title>Response by Yonker et al to Letter Regarding Article, "Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37695829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 12;148(11):910-911. doi: 10.1161/CIRCULATIONAHA.123.065629. Epub 2023 Sep 11.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37695829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37695829</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065629>10.1161/CIRCULATIONAHA.123.065629</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37695829</guid>
<pubDate>Mon, 11 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Lael M Yonker</dc:creator>
<dc:creator>Alessio Fasano</dc:creator>
<dc:creator>David R Walt</dc:creator>
<dc:date>2023-09-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Yonker et al to Letter Regarding Article, "Circulating Spike Protein Detected in Post-COVID-19 mRNA Vaccine Myocarditis"</dc:title>
<dc:identifier>pmid:37695829</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065629</dc:identifier>
</item>
<item>
<title>Hormonal gatekeeping via the blood-brain barrier governs caste-specific behavior in ants</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>Here, we reveal an unanticipated role of the blood-brain barrier (BBB) in regulating complex social behavior in ants. Using scRNA-seq, we find localization in the BBB of a key hormone-degrading enzyme called juvenile hormone esterase (Jhe), and we show that this localization governs the level of juvenile hormone (JH3) entering the brain. Manipulation of the Jhe level reprograms the brain transcriptome between ant castes. Although ant Jhe is retained and functions intracellularly within the BBB,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 24:S0092-8674(23)00856-5. doi: 10.1016/j.cell.2023.08.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Here, we reveal an unanticipated role of the blood-brain barrier (BBB) in regulating complex social behavior in ants. Using scRNA-seq, we find localization in the BBB of a key hormone-degrading enzyme called juvenile hormone esterase (Jhe), and we show that this localization governs the level of juvenile hormone (JH3) entering the brain. Manipulation of the Jhe level reprograms the brain transcriptome between ant castes. Although ant Jhe is retained and functions intracellularly within the BBB, we show that Drosophila Jhe is naturally extracellular. Heterologous expression of ant Jhe into the Drosophila BBB alters behavior in fly to mimic what is seen in ants. Most strikingly, manipulation of Jhe levels in ants reprograms complex behavior between worker castes. Our study thus uncovers a remarkable, potentially conserved role of the BBB serving as a molecular gatekeeper for a neurohormonal pathway that regulates social behavior.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37683635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37683635</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.002>10.1016/j.cell.2023.08.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37683635</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Linyang Ju</dc:creator>
<dc:creator>Karl M Glastad</dc:creator>
<dc:creator>Lihong Sheng</dc:creator>
<dc:creator>Janko Gospocic</dc:creator>
<dc:creator>Callum J Kingwell</dc:creator>
<dc:creator>Shawn M Davidson</dc:creator>
<dc:creator>Sarah D Kocher</dc:creator>
<dc:creator>Roberto Bonasio</dc:creator>
<dc:creator>Shelley L Berger</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Hormonal gatekeeping via the blood-brain barrier governs caste-specific behavior in ants</dc:title>
<dc:identifier>pmid:37683635</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.002</dc:identifier>
</item>
<item>
<title>Genetic manipulation of Patescibacteria provides mechanistic insights into microbial dark matter and the epibiotic lifestyle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>Patescibacteria, also known as the candidate phyla radiation (CPR), are a diverse group of bacteria that constitute a disproportionately large fraction of microbial dark matter. Its few cultivated members, belonging mostly to Saccharibacteria, grow as epibionts on host Actinobacteria. Due to a lack of suitable tools, the genetic basis of this lifestyle and other unique features of Patescibacteira remain unexplored. Here, we show that Saccharibacteria exhibit natural competence, and we exploit...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 30:S0092-8674(23)00906-6. doi: 10.1016/j.cell.2023.08.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Patescibacteria, also known as the candidate phyla radiation (CPR), are a diverse group of bacteria that constitute a disproportionately large fraction of microbial dark matter. Its few cultivated members, belonging mostly to Saccharibacteria, grow as epibionts on host Actinobacteria. Due to a lack of suitable tools, the genetic basis of this lifestyle and other unique features of Patescibacteira remain unexplored. Here, we show that Saccharibacteria exhibit natural competence, and we exploit this property for their genetic manipulation. Imaging of fluorescent protein-labeled Saccharibacteria provides high spatiotemporal resolution of phenomena accompanying epibiotic growth, and a transposon-insertion sequencing (Tn-seq) genome-wide screen reveals the contribution of enigmatic Saccharibacterial genes to growth on their hosts. Finally, we leverage metagenomic data to provide cutting-edge protein structure-based bioinformatic resources that support the strain Southlakia epibionticum and its corresponding host, Actinomyces israelii, as a model system for unlocking the molecular underpinnings of the epibiotic lifestyle.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37683634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37683634</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.017>10.1016/j.cell.2023.08.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37683634</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Yaxi Wang</dc:creator>
<dc:creator>Larry A Gallagher</dc:creator>
<dc:creator>Pia A Andrade</dc:creator>
<dc:creator>Andi Liu</dc:creator>
<dc:creator>Ian R Humphreys</dc:creator>
<dc:creator>Serdar Turkarslan</dc:creator>
<dc:creator>Kevin J Cutler</dc:creator>
<dc:creator>Mario L Arrieta-Ortiz</dc:creator>
<dc:creator>Yaqiao Li</dc:creator>
<dc:creator>Matthew C Radey</dc:creator>
<dc:creator>Jeffrey S McLean</dc:creator>
<dc:creator>Qian Cong</dc:creator>
<dc:creator>David Baker</dc:creator>
<dc:creator>Nitin S Baliga</dc:creator>
<dc:creator>S Brook Peterson</dc:creator>
<dc:creator>Joseph D Mougous</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Genetic manipulation of Patescibacteria provides mechanistic insights into microbial dark matter and the epibiotic lifestyle</dc:title>
<dc:identifier>pmid:37683634</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.017</dc:identifier>
</item>
<item>
<title>Epoxyeicosatrienoic Acids Prevent Cardiac Dysfunction in Viral Myocarditis via IFN-I Signaling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>Myocarditis is a challenging inflammatory disease of the heart, and better understanding of its pathogenesis is needed to develop specific drug therapies. Epoxyeicosatrienoic acids (EETs), active molecules synthesized by CYP (cytochrome P450) enzymes from arachidonic acids and hydrolyzed to less active dihydroxyeicosatrienoic acids by sEH (soluble epoxide hydrolase), have been attributed anti-inflammatory activity. Here, we investigated whether EETs have immunomodulatory activity and exert...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 8. doi: 10.1161/CIRCRESAHA.123.322619. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Myocarditis is a challenging inflammatory disease of the heart, and better understanding of its pathogenesis is needed to develop specific drug therapies. Epoxyeicosatrienoic acids (EETs), active molecules synthesized by CYP (cytochrome P450) enzymes from arachidonic acids and hydrolyzed to less active dihydroxyeicosatrienoic acids by sEH (soluble epoxide hydrolase), have been attributed anti-inflammatory activity. Here, we investigated whether EETs have immunomodulatory activity and exert protective effects on coxsackie B3 virus-induced myocarditis. Viral infection altered eicosanoid epoxide and diol levels in both patients with myocarditis and in the murine heart and correlated with the increased expression and activity of sEH after coxsackie B3 virus infection. Administration of a sEH inhibitor prevented coxsackie B3 virus-induced cardiac dysfunction and inflammatory infiltration. Importantly, EET/sEH inhibitor treatment attenuated viral infection or improved viral resistance by activating type I IFN (interferon) signaling. At the molecular level, EETs enhanced the interaction between GSK3β (glycogen synthase kinase-3 beta) and TBK1 (TANK-binding kinase 1) to promote IFN-β production. Our findings revealed that EETs and sEH inhibitors prevent the progress of coxsackie B3 virus-induced myocarditis, particularly by promoting viral resistance by increasing IFN production.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37681352/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37681352</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322619>10.1161/CIRCRESAHA.123.322619</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37681352</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Zhou Zhou</dc:creator>
<dc:creator>Min Zhang</dc:creator>
<dc:creator>Chengcheng Zhao</dc:creator>
<dc:creator>Xu Gao</dc:creator>
<dc:creator>Zheng Wen</dc:creator>
<dc:creator>Junfang Wu</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Ingrid Fleming</dc:creator>
<dc:creator>Jiong Hu</dc:creator>
<dc:creator>Dao Wen Wang</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Epoxyeicosatrienoic Acids Prevent Cardiac Dysfunction in Viral Myocarditis via IFN-I Signaling</dc:title>
<dc:identifier>pmid:37681352</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322619</dc:identifier>
</item>
<item>
<title>Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.065614. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are inconsistent between the US Food and Drug Administration and European Medicines Agency for patients with atrial fibrillation. Optimal apixaban dosing in chronic kidney disease remains unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: With the use of deidentified electronic health record data from the Optum Labs Data Warehouse, patients with atrial fibrillation and chronic kidney disease stage 4/5 initiating apixaban between 2013 and 2021 were identified. Risks of bleeding and stroke/systemic embolism were compared by apixaban dose (5 versus 2.5 mg), adjusted for baseline characteristics by the inverse probability of treatment weighting. The Fine-Gray subdistribution hazard model was used to account for the competing risk of death. Cox regression was used to examine risk of death by apixaban dose.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 4313 apixaban new users, 1705 (40%) received 5 mg and 2608 (60%) received 2.5 mg. Patients treated with 5 mg apixaban were younger (mean age, 72 versus 80 years), with greater weight (95 versus 80 kg) and higher serum creatinine (2.7 versus 2.5 mg/dL). Mean estimated glomerular filtration rate was not different between the groups (24 versus 24 mL·min<sup>-1</sup>·1.73 m<sup>-2</sup>). In inverse probability of treatment weighting analysis, apixaban 5 mg was associated with a higher risk of bleeding (incidence rate 4.9 versus 2.9 events per 100 person-years; incidence rate difference, 2.0 [95% CI, 0.6-3.4] events per 100 person-years; subdistribution hazard ratio, 1.63 [95% CI, 1.04-2.54]). There was no difference between apixaban 5 mg and 2.5 mg groups in the risk of stroke/systemic embolism (3.3 versus 3.0 events per 100 person-years; incidence rate difference, 0.2 [95% CI, -1.0 to 1.4] events per 100 person-years; subdistribution hazard ratio, 1.01 [95% CI, 0.59-1.73]), or death (9.9 versus 9.4 events per 100 person-years; incidence rate difference, 0.5 [95% CI, -1.6 to 2.6] events per 100 person-years; hazard ratio, 1.03 [95% CI, 0.77-1.38]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37681341/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37681341</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065614>10.1161/CIRCULATIONAHA.123.065614</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37681341</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Yunwen Xu</dc:creator>
<dc:creator>Alex R Chang</dc:creator>
<dc:creator>Lesley A Inker</dc:creator>
<dc:creator>Mara McAdams-DeMarco</dc:creator>
<dc:creator>Morgan E Grams</dc:creator>
<dc:creator>Jung-Im Shin</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease</dc:title>
<dc:identifier>pmid:37681341</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065614</dc:identifier>
</item>
<item>
<title>Changes in Cardiovascular Spending, Care Utilization, and Clinical Outcomes Associated With Participation in Bundled Payments for Care Improvement Advanced</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Participation in BPCI-A was not associated with spending reductions, changes in care use, or quality improvements for the cardiovascular medical events or procedures offered in the model.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.065109. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Bundled Payments for Care Improvement Advanced (BPCI-A) is a Medicare initiative that aims to incentivize reductions in spending for episodes of care that start with a hospitalization and end 90 days after discharge. Cardiovascular disease, an important driver of Medicare spending, is one of the areas of focus BPCI-A. It is unknown whether BPCI-A is associated with spending reductions or quality improvements for the 3 cardiovascular medical events or 5 cardiovascular procedures in the model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this retrospective cohort study, we conducted difference-in-differences analyses using Medicare claims for patients discharged between January 1, 2017, and September 30, 2019, to assess differences between BPCI-A hospitals and matched nonparticipating control hospitals. Our primary outcomes were the differential changes in spending, before versus after implementation of BPCI-A, for cardiac medical and procedural conditions at BPCI-A hospitals compared with controls. Secondary outcomes included changes in patient complexity, care use, healthy days at home, readmissions, and mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Baseline spending for cardiac medical episodes at BPCI-A hospitals was $25 606. The differential change in spending for cardiac medical episodes at BPCI-A versus control hospitals was $16 (95% CI, -$228 to $261; <i>P</i>=0.90). Baseline spending for cardiac procedural episodes at BPCI-A hospitals was $37 961. The differential change in spending for cardiac procedural episodes was $171 (95% CI, -$429 to $772; <i>P</i>=0.58). There were minimal differential changes in physicians' care patterns such as the complexity of treated patients or in their care use. At BPCI-A versus control hospitals, there were no significant differential changes in rates of 90-day readmissions (differential change, 0.27% [95% CI, -0.25% to 0.80%] for medical episodes; differential change, 0.31% [95% CI, -0.98% to 1.60%] for procedural episodes) or mortality (differential change, -0.14% [95% CI, -0.50% to 0.23%] for medical episodes; differential change, -0.36% [95% CI, -1.25% to 0.54%] for procedural episodes).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Participation in BPCI-A was not associated with spending reductions, changes in care use, or quality improvements for the cardiovascular medical events or procedures offered in the model.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37681315/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37681315</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065109>10.1161/CIRCULATIONAHA.123.065109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37681315</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Sukruth A Shashikumar</dc:creator>
<dc:creator>Jie Zheng</dc:creator>
<dc:creator>E John Orav</dc:creator>
<dc:creator>Arnold M Epstein</dc:creator>
<dc:creator>Karen E Joynt Maddox</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Changes in Cardiovascular Spending, Care Utilization, and Clinical Outcomes Associated With Participation in Bundled Payments for Care Improvement Advanced</dc:title>
<dc:identifier>pmid:37681315</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065109</dc:identifier>
</item>
<item>
<title>Extracellular Perinexal Separation Is a Principal Determinant of Cardiac Conduction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37681314/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Cardiac conduction does not correlate with extracellular resistance but is biphasically related to perinexal separation, providing evidence that the relationship between CV and extracellular volume is determined by ephaptic mechanisms under conditions of normal gap junctional coupling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 8. doi: 10.1161/CIRCRESAHA.123.322567. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac conduction is understood to occur through gap junctions. Recent evidence supports ephaptic coupling as another mechanism of electrical communication in the heart. Conduction via gap junctions predicts a direct relationship between conduction velocity (CV) and bulk extracellular resistance. By contrast, ephaptic theory is premised on the existence of a biphasic relationship between CV and the volume of specialized extracellular clefts within intercalated discs such as the perinexus. Our objective was to determine the relationship between ventricular CV and structural changes to micro- and nanoscale extracellular spaces.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Conduction and Cx43 (connexin43) protein expression were quantified from optically mapped guinea pig whole-heart preparations perfused with the osmotic agents albumin, mannitol, dextran 70 kDa, or dextran 2 MDa. Peak sodium current was quantified in isolated guinea pig ventricular myocytes. Extracellular resistance was quantified by impedance spectroscopy. Intercellular communication was assessed in a heterologous expression system with fluorescence recovery after photobleaching. Perinexal width was quantified from transmission electron micrographs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: CV primarily in the transverse direction of propagation was significantly reduced by mannitol and increased by albumin and both dextrans. The combination of albumin and dextran 70 kDa decreased CV relative to albumin alone. Extracellular resistance was reduced by mannitol, unchanged by albumin, and increased by both dextrans. Cx43 expression and conductance and peak sodium currents were not significantly altered by the osmotic agents. In response to osmotic agents, perinexal width, in order of narrowest to widest, was albumin with dextran, 70 kDa; albumin or dextran, 2 MDa; dextran, 70 kDa or no osmotic agent, and mannitol. When compared in the same order, CV was biphasically related to perinexal width.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Cardiac conduction does not correlate with extracellular resistance but is biphasically related to perinexal separation, providing evidence that the relationship between CV and extracellular volume is determined by ephaptic mechanisms under conditions of normal gap junctional coupling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37681314/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37681314</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322567>10.1161/CIRCRESAHA.123.322567</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37681314</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>William P Adams</dc:creator>
<dc:creator>Tristan B Raisch</dc:creator>
<dc:creator>Yajun Zhao</dc:creator>
<dc:creator>Rafael Davalos</dc:creator>
<dc:creator>Sarah Barrett</dc:creator>
<dc:creator>D Ryan King</dc:creator>
<dc:creator>Chandra B Bain</dc:creator>
<dc:creator>Katrina Colucci-Chang</dc:creator>
<dc:creator>Grace A Blair</dc:creator>
<dc:creator>Alexandra Hanlon</dc:creator>
<dc:creator>Alicia Lozano</dc:creator>
<dc:creator>Rengasayee Veeraraghavan</dc:creator>
<dc:creator>Xiaoping Wan</dc:creator>
<dc:creator>Isabelle Deschene</dc:creator>
<dc:creator>James W Smyth</dc:creator>
<dc:creator>Gregory S Hoeker</dc:creator>
<dc:creator>Robert G Gourdie</dc:creator>
<dc:creator>Steven Poelzing</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Extracellular Perinexal Separation Is a Principal Determinant of Cardiac Conduction</dc:title>
<dc:identifier>pmid:37681314</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322567</dc:identifier>
</item>
<item>
<title>Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.064170. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Clonal hematopoiesis (CH), which results from an array of nonmalignant driver gene mutations, can lead to altered immune cell function and chronic disease, and has been associated with worse outcomes in patients with heart failure (HF) with reduced ejection fraction. However, the role of CH in the prognosis of HF with preserved ejection fraction (HFpEF) has been understudied. This study aimed to characterize CH in patients with HFpEF and elucidate its causal role in a murine model.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using a panel of 20 candidate CH driver genes and a variant allele frequency cutoff of 0.5%, ultradeep error-corrected sequencing identified CH in a cohort of 81 patients with HFpEF (mean age, 71±6 years; ejection fraction, 63±5%) and 36 controls without a diagnosis of HFpEF (mean age, 74±7 years; ejection fraction, 61.5±8%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with controls, there was an enrichment of <i>TET2</i>-mediated CH in the HFpEF patient cohort (12% versus 0%, respectively; <i>P</i>=0.02). In the HFpEF cohort, patients with CH exhibited exacerbated diastolic dysfunction in terms of E/e' (14.9 versus 11.7, respectively; <i>P</i>=0.0096) and E/A (1.69 versus 0.89, respectively; <i>P</i>=0.0206) compared with those without CH. The association of CH with exacerbated diastolic dysfunction was corroborated in a validation cohort of 59 individuals with HFpEF. In accordance, patients with HFpEF with CH and age ≥70 years exhibited worse prognosis in terms of 5-year cardiovascular-related hospitalization rate (hazard ratio, 5.06; <i>P</i>=0.042) compared with patients with HFpEF without CH and age ≥70 years. To investigate the causal role of CH in HFpEF, nonconditioned mice underwent adoptive transfer with <i>Tet2</i>-wild-type or <i>Tet2</i>-deficient bone marrow and were subsequently subjected to a high-fat diet/L-NAME (N<sub>ω</sub>-nitro-l-arginine methyl ester) combination treatment to induce features of HFpEF. This model of <i>Tet2</i>-CH exacerbated cardiac hypertrophy by heart weight/tibia length and cardiomyocyte size, diastolic dysfunction by E/e' and left ventricular end-diastolic pressure, and cardiac fibrosis compared with the <i>Tet2</i>-wild-type condition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of <i>Tet2</i>-mediated CH displays greater features of HFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37681311</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064170>10.1161/CIRCULATIONAHA.123.064170</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37681311</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jesse Cochran</dc:creator>
<dc:creator>Yoshimitsu Yura</dc:creator>
<dc:creator>Mark C Thel</dc:creator>
<dc:creator>Heather Doviak</dc:creator>
<dc:creator>Ariel H Polizio</dc:creator>
<dc:creator>Yuka Arai</dc:creator>
<dc:creator>Yohei Arai</dc:creator>
<dc:creator>Keita Horitani</dc:creator>
<dc:creator>Eunbee Park</dc:creator>
<dc:creator>Nicholas W Chavkin</dc:creator>
<dc:creator>Anupreet Kour</dc:creator>
<dc:creator>Soichi Sano</dc:creator>
<dc:creator>Nitin Mahajan</dc:creator>
<dc:creator>Megan Evans</dc:creator>
<dc:creator>Mahalia Huba</dc:creator>
<dc:creator>Nadia Martinez Naya</dc:creator>
<dc:creator>Hanna Sun</dc:creator>
<dc:creator>Youngho Ban</dc:creator>
<dc:creator>Karen K Hirschi</dc:creator>
<dc:creator>Stefano Toldo</dc:creator>
<dc:creator>Antonio Abbate</dc:creator>
<dc:creator>Todd E Druley</dc:creator>
<dc:creator>Frederick L Ruberg</dc:creator>
<dc:creator>Mathew S Maurer</dc:creator>
<dc:creator>Justin A Ezekowitz</dc:creator>
<dc:creator>Jason R B Dyck</dc:creator>
<dc:creator>Kenneth Walsh</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:37681311</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.064170</dc:identifier>
</item>
<item>
<title>Cardiac Aging Is Promoted by Pseudohypoxia Increasing p300-Induced Glycolysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37681309/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Taken together, our results suggest how epigenetic dysregulation of glycolysis pathway enhancers could potentially be targeted to treat heart failure in the elderly.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 8. doi: 10.1161/CIRCRESAHA.123.322676. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RATIONALE: Heart failure is typical in the elderly. Metabolic remodeling of cardiomyocytes underlies inexorable deterioration of cardiac function with aging: glycolysis increases at the expense of oxidative phosphorylation, causing an energy deficit contributing to impaired contractility. Better understanding of the mechanisms of this metabolic switching could be critical for reversing the condition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the role of 3 histone modifications (H3K27ac, H3K27me3, and H3K4me1) in the metabolic remodeling occurring in the aging heart.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We report a set of species-conserved enhancers associated with transcriptional changes underlying age-related metabolic remodeling in cardiomyocytes. Activation of the enhancer region of <i>Hk2</i>-a key glycolysis pathway gene-was fostered in old age-onset mouse heart by pseudohypoxia, wherein hypoxia-related genes are expressed under normal O<sub>2</sub> levels, via increased activity of the transcriptional coactivator p300 (E1A-associated binding protein p300)/CBP (CREB-binding protein). Pharmacological inhibition of p300/CBP before the onset of cardiac aging led to a more aerobic, less glycolytic, metabolic state, improved heart contractility, and overall blunting of cardiac decline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Taken together, our results suggest how epigenetic dysregulation of glycolysis pathway enhancers could potentially be targeted to treat heart failure in the elderly.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37681309/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37681309</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322676>10.1161/CIRCRESAHA.123.322676</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37681309</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Simone Serio</dc:creator>
<dc:creator>Christina Pagiatakis</dc:creator>
<dc:creator>Elettra Musolino</dc:creator>
<dc:creator>Arianna Felicetta</dc:creator>
<dc:creator>Pierluigi Carullo</dc:creator>
<dc:creator>Javier Laura Frances</dc:creator>
<dc:creator>Laura Papa</dc:creator>
<dc:creator>Giacomo Rozzi</dc:creator>
<dc:creator>Nicolò Salvarani</dc:creator>
<dc:creator>Michele Miragoli</dc:creator>
<dc:creator>Rosalba Gornati</dc:creator>
<dc:creator>Giovanni Bernardini</dc:creator>
<dc:creator>Gianluigi Condorelli</dc:creator>
<dc:creator>Roberto Papait</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cardiac Aging Is Promoted by Pseudohypoxia Increasing p300-Induced Glycolysis</dc:title>
<dc:identifier>pmid:37681309</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322676</dc:identifier>
</item>
<item>
<title>An apple in the heart: a rare case of cardiac hyper-immunoglobulin E syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37680109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 8:ehad565. doi: 10.1093/eurheartj/ehad565. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37680109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37680109</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad565>10.1093/eurheartj/ehad565</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37680109</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jie Yin</dc:creator>
<dc:creator>Xiao-Hang Liu</dc:creator>
<dc:creator>Wei Chen</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>An apple in the heart: a rare case of cardiac hyper-immunoglobulin E syndrome</dc:title>
<dc:identifier>pmid:37680109</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad565</dc:identifier>
</item>
<item>
<title>Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37680108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 8:ehad593. doi: 10.1093/eurheartj/ehad593. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37680108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37680108</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad593>10.1093/eurheartj/ehad593</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37680108</guid>
<pubDate>Fri, 08 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Giovanna Liuzzo</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2023-09-08</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges</dc:title>
<dc:identifier>pmid:37680108</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad593</dc:identifier>
</item>
<item>
<title>Menopause-Biology, consequences, supportive care, and therapeutic options</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37678251/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>Menopause is the cessation of ovarian function, with loss of reproductive hormone production and irreversible loss of fertility. It is a natural part of reproductive aging. The physiology of the menopause is complex and incompletely understood. Globally, menopause occurs around the age of 49 years, with geographic and ethnic variation. The hormonal changes of the menopause transition may result in both symptoms and long-term systemic effects, predominantly adverse effects on cardiometabolic and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 5:S0092-8674(23)00905-4. doi: 10.1016/j.cell.2023.08.016. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Menopause is the cessation of ovarian function, with loss of reproductive hormone production and irreversible loss of fertility. It is a natural part of reproductive aging. The physiology of the menopause is complex and incompletely understood. Globally, menopause occurs around the age of 49 years, with geographic and ethnic variation. The hormonal changes of the menopause transition may result in both symptoms and long-term systemic effects, predominantly adverse effects on cardiometabolic and musculoskeletal health. The most effective treatment for bothersome menopausal symptoms is evidence-based, menopausal hormone therapy (MHT), which reduces bone loss and may have cardiometabolic benefits. Evidence-based non-hormonal interventions are also available for symptom relief. Treatment should be individualized with shared decision-making. Most MHT regimens are not regulator approved for perimenopausal women. Studies that include perimenopausal women are needed to determine the efficacy and safety of treatment options. Further research is crucial to improve menopause care, along with research to guide policy and clinical practice.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37678251/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37678251</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.016>10.1016/j.cell.2023.08.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37678251</guid>
<pubDate>Thu, 07 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Susan R Davis</dc:creator>
<dc:creator>JoAnn Pinkerton</dc:creator>
<dc:creator>Nanette Santoro</dc:creator>
<dc:creator>Tommaso Simoncini</dc:creator>
<dc:date>2023-09-07</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Menopause-Biology, consequences, supportive care, and therapeutic options</dc:title>
<dc:identifier>pmid:37678251</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.016</dc:identifier>
</item>
<item>
<title>Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37676198/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: As few as about 2,600 and about 2,800 steps/d yield significant mortality and CVD benefits, with progressive risk reductions up to about 8,800 and about 7,200 steps/d, respectively. Additional mortality benefits were found at a moderate to high vs a low step cadence. These findings can extend contemporary physical activity prescriptions given the easy-to-understand concept of step count. (Dose-Response Relationship Between Daily Step Count and Health Outcomes: A Systematic Review...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 26:S0735-1097(23)06400-8. doi: 10.1016/j.jacc.2023.07.029. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The minimal and optimal daily step counts for health improvements remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: A meta-analysis was performed to quantify dose-response associations of objectively measured step count metrics in the general population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Electronic databases were searched from inception to October 2022. Primary outcomes included all-cause mortality and incident cardiovascular disease (CVD). Study results were analyzed using generalized least squares and random-effects models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In total, 111,309 individuals from 12 studies were included. Significant risk reductions were observed at 2,517 steps/d for all-cause mortality (adjusted HR [aHR]: 0.92; 95% CI: 0.84-0.999) and 2,735 steps/d for incident CVD (aHR: 0.89; 95% CI: 0.79-0.999) compared with 2,000 steps/d (reference). Additional steps resulted in nonlinear risk reductions of all-cause mortality and incident CVD with an optimal dose at 8,763 (aHR: 0.40; 95% CI: 0.38-0.43) and 7,126 steps/d (aHR: 0.49; 95% CI: 0.45-0.55), respectively. Increments from a low to an intermediate or a high cadence were independently associated with risk reductions of all-cause mortality. Sex did not influence the dose-response associations, but after stratification for assessment device and wear location, pronounced risk reductions were observed for hip-worn accelerometers compared with pedometers and wrist-worn accelerometers.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: As few as about 2,600 and about 2,800 steps/d yield significant mortality and CVD benefits, with progressive risk reductions up to about 8,800 and about 7,200 steps/d, respectively. Additional mortality benefits were found at a moderate to high vs a low step cadence. These findings can extend contemporary physical activity prescriptions given the easy-to-understand concept of step count. (Dose-Response Relationship Between Daily Step Count and Health Outcomes: A Systematic Review and Meta-Analyses; CRD42021244747).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37676198/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37676198</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.029>10.1016/j.jacc.2023.07.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37676198</guid>
<pubDate>Thu, 07 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Niels A Stens</dc:creator>
<dc:creator>Esmée A Bakker</dc:creator>
<dc:creator>Asier Mañas</dc:creator>
<dc:creator>Laurien M Buffart</dc:creator>
<dc:creator>Francisco B Ortega</dc:creator>
<dc:creator>Duck-Chul Lee</dc:creator>
<dc:creator>Paul D Thompson</dc:creator>
<dc:creator>Dick H J Thijssen</dc:creator>
<dc:creator>Thijs M H Eijsvogels</dc:creator>
<dc:date>2023-09-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events</dc:title>
<dc:identifier>pmid:37676198</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.029</dc:identifier>
</item>
<item>
<title>Reducing Mortality and Cardiovascular Disease: Stepping Up Our Game</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37676197/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Aug 28:S0735-1097(23)06401-X. doi: 10.1016/j.jacc.2023.08.007. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37676197/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37676197</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.007>10.1016/j.jacc.2023.08.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37676197</guid>
<pubDate>Thu, 07 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Carl J Lavie</dc:creator>
<dc:creator>Charles A German</dc:creator>
<dc:creator>Fabian Sanchis-Gomar</dc:creator>
<dc:date>2023-09-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reducing Mortality and Cardiovascular Disease: Stepping Up Our Game</dc:title>
<dc:identifier>pmid:37676197</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.007</dc:identifier>
</item>
<item>
<title>Correction to: Lifelong endurance exercise and its relation with coronary atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37675842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230912060825&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 7:ehad546. doi: 10.1093/eurheartj/ehad546. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37675842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230912060825&v=2.17.9.post6+86293ac">37675842</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad546>10.1093/eurheartj/ehad546</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37675842</guid>
<pubDate>Thu, 07 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Lifelong endurance exercise and its relation with coronary atherosclerosis</dc:title>
<dc:identifier>pmid:37675842</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad546</dc:identifier>
</item>





























</channel>
</rss>